BioVaxys Announces Issuance of DPX Related Patent from the U.S. Patent and Trademark Office

BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Issuance of this Patent by the USPTO expands the value of our IP and DPX platform, and puts the Company on strong footing for further development and partnering with companies developing epitope-based vaccines for diseases such as chronic hepatitis-B, influenza, and RSV, where we have such promising ...read more